Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control

Use of Continuous Glucose Monitoring Combined With Ambulatory Glucose Profiles to Characterize Glycemic Control Addendum to: A Randomized, Double-Blind, Parallel-Group, Multicenter Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Long-Acting Release to Those of Sitagliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus Treated With Metformin (Study BCB106)

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00806520

Enrollment

Registered

2008-12-10

Start date

2008-04-30

Completion date

2011-08-31

Last updated

2015-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Keywords

Continuous Glucose Monitoring, Exenatide Once Weekly or, Januvia or, Actos

Brief summary

Obtain Continuous Glucose Monitoring (CGM) data from individuals taking exenatide LAR, sitagliptin, or pioglitazone. The CGM measurements collected will help determine the characteristics of glucose control prior to treatment and during treatment.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* 18 years or older * type 2 diabetes * A1c 7.1 - 11 * BMI 25 - 45 * stable weight for 3 months before screening * fasting glucose \< 280 at screening * stable dose of metformin for at least 2 months before screening * not being treated with or on a stable dose of hormone replacement therapy, oral contraceptives, anti-hypertensive agents, lipid lowering agents, thyroid replacement therapy, anti-depressants, drugs known to affect body weight * male or female, non-lactating, non-pregnant and willing to use birth control * lab values that are not clinically significant at screening * physical exam and ECG that are not clinically significant at screening * able to read, understand, and sign consent form

Exclusion criteria

* liver disease * renal disease * cardiovascular disease * gastroparesis * cancer within 5 years of screening * macular edema * chronic infections * drug or alcohol abuse * fasting triglycerides \> or = 600 at screening * previous exposure to exenatide LAR * has donated blood within 60 days of screening or is planning to donate during the study * has had a major surgery or blood transfusion within 2 months before screening * is currently being treated or is expecting to be treated with Byetta, Januvia, SU, TZD, GLP-1 analog, alpha-glucosidase inhibitor, meglitinide, nateglinide, symlin, insulin, systemic corticosteroids, lopid or rifampin * has received an investigational drug within 1 month before screening * has allergies or hypersensitivity to any component of the study drug * has previously had an adverse event related to TZD or Januvia * is an immediate family member of the study sight or directly affiliated * is employed by Amylin, Lilly or Alkermes

Countries

United States

Outcome results